BofA raised the firm’s price target on Universal Health (UHS) to $215 from $190 and keeps an Underperform rating on the shares. The firm updated estimates with the company’s guidance and rolls out its 2028 view, but reiterates an Underperform rating as it sees UHS having above average exposure to the policy changes while the core results remain weak.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UHS:
- Sell Rating on Universal Health: Weaker Underlying Demand, Policy Risks, and Overvalued Shares Support Underperform Stance
- Universal Health price target raised to $268 from $262 at Barclays
- Closing Bell Movers: Nvidia pares post-earnings gains
- Universal Health reports Q4 EPS $5.88, consensus $5.90
- Universal Health sees FY26 adjusted EPS $22.64-$24.52, consensus $23.52